Logo Logo Logo
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical


      • AR-401

    • Out-licensed Products


      • AR-105 (Aerucin®)


      • AR-101 (Aerumab™)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • APEXTM


    • MabIgX®


    • Therapeutic Targets


      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Tosatoxumab)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical



      • AR-401

    • Out-licensed Products



      • AR-105 (Aerucin®)


      • AR-101 (AerumabTM)


      • AR-201
  • TECHNOLOGY


    • Overview


    • MabIgX®


    • Therapeutic Targets



      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
Search:
 



Investors

Aridis Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2016Calendar Year 2015Calendar Year 2014
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
S-1Registration statement for face-amount certificate companiesMay 22, 2023Open Registration statement for face-amount certificate companies in HTML.Open Registration statement for face-amount certificate companies in DOC file.Open Registration statement for face-amount certificate companies in PDF file.Open Registration statement for face-amount certificate companies in XLS file.
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Mar 16, 2023Open Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 in HTML.Open Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 in DOC file.Open Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 in PDF file.Open Form of prospectus disclosing information facts events covered in both forms 424B2 424B3 in XLS file.

CONTACT US

Aridis Pharmaceuticals Inc.
983 University Ave Suite B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-960-3822

 

ADDITIONAL INFORMATION

Site Map
Privacy Policy
Financial Conflict of Interest Policy